Hypoxia-inducible factor 1 (HIF-1) (HIF-1)

Hypoxia-inducible factor 1 is a heterodimeric transcription factor composed primarily of an inducible alpha subunit (HIF‑1α) and a constitutive beta subunit. It acts as the master regulator enabling cells to adapt their metabolism, survival, proliferation, angiogenesis, and erythropoiesis under low oxygen conditions. Under normoxic conditions, prolyl hydroxylases mark the alpha subunit for rapid degradation; during hypoxia this process is inhibited allowing stabilization and nuclear translocation where it activates genes with hypoxia-responsive elements. Dysregulation or overexpression—especially seen in tumors—drives aggressive cancer phenotypes through metabolic reprogramming (“Warburg effect”), increased blood vessel formation, resistance to therapy, invasion/metastasis potential, but also plays roles in ischemia adaptation and tissue repair/regeneration. Therapeutic targeting focuses on inhibiting its function or stability mainly for oncology indications but faces challenges due to its essential physiological roles across tissues.[2][3][4]

Other names

HIF-1Hypoxia-inducible factor 1-alpha (for the alpha subunit)HIF-1αHIF

- Inhibition of transcriptional activity by blocking dimerization or DNA binding of HIF‑1α - Promotion of degradation or inhibition of synthesis/stabilization of HIF‑1α protein under hypoxic conditions - Indirect modulation via upstream signaling pathways affecting oxygen sensing/prolyl hydroxylase activity